Market capitalization | $203.48m |
Enterprise Value | $137.07m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.56 |
P/S ratio (TTM) P/S ratio | 2.32 |
P/B ratio (TTM) P/B ratio | 2.20 |
Revenue growth (TTM) Revenue growth | 3.38% |
Revenue (TTM) Revenue | $87.69m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
12 Analysts have issued a Y-mAbs Therapeutics, Inc. forecast:
12 Analysts have issued a Y-mAbs Therapeutics, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 88 88 |
3%
3%
|
|
Gross Profit | 73 73 |
1%
1%
|
|
EBITDA | -31 -31 |
23%
23%
|
EBIT (Operating Income) EBIT | -31 -31 |
22%
22%
|
Net Profit | -30 -30 |
38%
38%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Head office | United States |
CEO | Michael Rossi |
Employees | 107 |
Founded | 2015 |
Website | www.ymabs.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.